Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406470 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
A Phase 3 study, sponsored by Green Cross Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT01406470: Completed Phase 3 study, sponsored by Green Cross Corporation.
NCT01406470 is a Phase 3 study that has completed, run by Green Cross Corporation. The registered enrollment target is 45 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01406470, a Phase 3 study, has completed, sponsored by Green Cross Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.
Interventions
- DRUG Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
What the finished NCT01406470 record still lists
NCT01406470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ is the first listed.
NCT01406470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01406470 about?
NCT01406470 is a clinical study titled "Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency". The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.
What is the current status of trial NCT01406470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2011-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01406470?
The interventions under investigation include: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ (DRUG).
Who is sponsoring clinical trial NCT01406470?
This trial is sponsored by Green Cross Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01406470's enrollment target sits among peer trials
45 1870th of 2000 higher than 127 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia